Β© 2026 CellCarta - All rights reserved.
When you run a biomarker program out of Australia, you're managing a complex system: whether youβre a local pilot or connected to trial sites spanning the globe, every sample matters. Add a time zone that puts you hours ahead of your sponsors in North America and Europe, and logistics can get complicated.
CellCarta built its Australian presence to make immune monitoring more simple. Our lab in Sydney runs on the same protocols, platforms, and quality standards as CellCarta's labs in North America, the EU, and China, so a PBMC sample processed in Sydney generates data directly comparable to one processed anywhere else in our network. Discover our specialist immunology CRO services delivering reliable, regulatory-ready data.
Quality isn't a checkpoint, it's how we work. We can support your immunology programs across all phases of development, from first-in-human through pivotal trials, with a local Australian flow cytometry centre and the scientific depth and operational discipline to protect your data at every step.
β Science-led biomarker selection and assay development
β Globally harmonized laboratories, including our Sydney site
β All phases of clinical development supported
β Regulatory-ready data for the TGA, FDA, EMA, and beyond
Across therapeutics and modalities, flow cytometry can provide key insights. From CAR-T detection and enumeration to TBNK and TBNK+CD20 panels to receptor occupancy assays and more, our Off-The-Shelf and custom panels help advance studies with high quality data.
Local isolation and storage of PBMCs allows reduced time in shipping. Isolated PBMCs can be used for further downstream application such as flow cytometry, mass spectrometry, and ELISpot.
Immune monitoring decisions shape the trajectory of your clinical program. Extended shipping timelines, misaligned biomarkers, insufficient assay sensitivity, or cross-site variability can delay timelines and compromise confidence in your data, especially when a program spans Australia alongside other regions.
Our Australia-based immunology team works within the same harmonized quality systems as our labs in North America, Australia, and China, so sponsors running programs in the region get local scientific depth without sacrificing global consistency.
Isolation and storage of cfDNA for further downstream application such as next-generation sequencing (NGS), providing multimodal monitoring options.
25 years of clinical biomarker and therapeutic knowledge that allows us to anticipate and reduce risk
Dedicated Project Manager and Scientists for each project, working as an extension of your team
Trusted by top 10 emerging biotech start-ups and & 20/20 leading large pharma companies
Worldwide footprint: our immunology labs are in North America, Europe, China, Australia
Handling all assays: from complex to routine
With an immunology team based in Australia and connected to CellCarta's global lab network, the right biomarker strategy does more than generate data. It builds the kind of confidence that holds up in every submission, across every region, through every phase.
Quality starts with people. Our Australia-based team of PhD-level scientists brings deep, hands-on expertise in flow cytometry and immunology, actively contributing to the scientific community through participation in worldwide conferences. By staying closely connected to the latest advancements, we ensure our approaches remain at the forefront of innovation while grounded in proven methodologies .
Built for reliability, our multi-site infrastructure, including our Australia laboratory, provides true operational resilience. With established assay transfer capabilities and seamless cross-lab coordination, we maintain continuity even in the face of shifting timelines or unexpected disruptions. This means fewer delays, stronger data integrity, and a partner you can depend on to keep your studies on track.
Quality starts with people. Our team of PhD-level scientists brings deep, hands-on expertise in flow cytometry and immunology, actively contributing to the scientific community through participation in worldwide conferences. By staying closely connected to the latest advancements, we ensure our approaches remain at the forefront of innovation while grounded in proven methodologies .
Immune monitoring decisions shape the trajectory of your clinical program. Misaligned biomarkers, insufficient assay sensitivity, or cross-site variability can delay timelines and compromise confidence in your data.
Quality matters at every stage. With a specialist immunology CRO, the right biomarker strategy does more than generate data. It builds the kind of confidence that holds up in every submission, across every region, through every phase.
Across therapeutics and modalities, flow cytometry can provide key insights. From CAR-T detection and enumeration to TBNK and TBNK+CD20 panels to receptor occupancy assays and more, our Off-The-Shelf and custom panels help advance studies with high quality data.
Local isolation and storage of PBMCs allows reduced time in shipping. Isolated PBMCs can be used for further downstream application such as flow cytometry, mass spectrometry, and ELISpot.
Isolation and storage of cfDNA for further downstream application such as next-generation sequencing (NGS), providing multimodal monitoring options.
Our Australia-based immunology team works within the same harmonized quality systems as our labs in North America, Australia, and China, so sponsors running programs in the region get local scientific depth without sacrificing global consistency.
25 years of clinical biomarker and therapeutic knowledge that allows us to anticipate and reduce risk
Dedicated Project Manager and Scientists for each project, working as an extension of your team
Trusted by top 10 emerging biotech start-ups and & 20/20 leading large pharma companies
Worldwide footprint: our immunology labs are in North America, Europe, China, Australia
Handling all assays: from complex to routine